BeiGene, Ltd. (SHA:688235)
Market Cap | 192.33B |
Revenue (ttm) | 27.81B |
Net Income (ttm) | -4.71B |
Shares Out | n/a |
EPS (ttm) | -44.70 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 2,572,704 |
Average Volume | 3,031,420 |
Open | 235.01 |
Previous Close | 239.00 |
Day's Range | 229.10 - 250.10 |
52-Week Range | 111.22 - 258.00 |
Beta | 0.49 |
RSI | 52.59 |
Earnings Date | May 14, 2025 |
About BeiGene
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a mo... [Read more]
Financial Performance
In 2024, BeiGene's revenue was $3.81 billion, an increase of 54.96% compared to the previous year's $2.46 billion. Losses were -$644.79 million, -26.87% less than in 2023.
Financial numbers in USD Financial StatementsNews

BeiGene Discontinues Lung Cancer Drug Study After Interim Data Showed Limited Survival Benefit
BeiGene Ltd (NASDAQ: ONC) on Thursday announced the discontinuation of its clinical development program for ociperlimab (BGB-A1217), an anti-TIGIT antibody, as a potential treatment for lung cancer ....
BeiGene slips on decision to halt lung cancer program

BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today ...

China-Based Biotech BeiGene Scores FDA Approval For Tevimbra/Chemo Combo For Untreated Patients With Esophageal Cancer
BeiGene's Tevimbra wins FDA approval for ... Full story available on Benzinga.com
BeiGene wins FDA nod for Tevimbra in first-line esophageal cancer
BeiGene: Q4 Results Impress With Positive Earnings Expected In 2025
Q4 2024 Beigene Ltd Earnings Presentation Transcript
Q4 2024 Beigene Ltd Earnings Presentation Transcript
BeiGene, Ltd. (ONC) Q4 2024 Earnings Call Transcript
BeiGene Ltd (ONC) Q4 2024 Earnings: EPS of -$0.11 Beats Estimates, Revenue Surges to $1.1 Billion
BeiGene Ltd (ONC) Q4 2024 Earnings: EPS of -$0.11 Beats Estimates, Revenue Surges to $1.1 Billion
BeiGene reports Q4 results

Hang Seng Index left untouched, but tweaks made to tech, China enterprises indices
Tencent Music and Horizon Robotics added to Hang Seng Tech Index, while ZTO Express and BeiGene added to Hang Seng China Enterprises Index.
BeiGene (ONC) Stock Rises on Nomura's Optimistic Outlook
BeiGene (ONC) Stock Rises on Nomura's Optimistic Outlook

ImmunityBio announces collaboration with Beigene
ImmunityBio partners with BeiGene for Phase 3 trial combining tislelizumab and ANKTIVA to improve survival in non-small cell lung cancer patients.